Table Info

Table 1.

Alterations of SCFA levels in neuroinflammatory disorders

Pathology	SCFA	Effect	Reference
MS	↓ Propionate in stool and serum	Reduced Treg number, metabolism, and function. Increased Th17 number.	[14, 19]
MS	↓ Propionate in faeces and acetate in plasma	Reduced SCFA promotes an inflammatory phenotype in gut mucosal T cells.	[9, 15]
AD	↓ Butyrate	AD patients with brain amyloid accumulation and endothelial dysfunction had decreased blood butyrate.	[20, 21]
AD	↓ Butyrate	In faeces and brain of APP/PS1 AD mice model. Butyrate can hinder the oligomerization of amyloid-β 1-40.	[22, 23]
PD	↓ SCFA in faeces	Significant decline of butyrate, acetate, and propionate in faecal of PD individuals compared to controls.	[18, 24]
PD	↓ Acetate ↑ Butyrate and propionate in faeces	Microbiota-derived SCFA regulates motor deficits and neuroinflammation in mouse models.	[17]

Declarations

Author contributions

CP: Conceptualization, Writing—original draft, Writing—review & editing. RP: Conceptualization, Writing—review & editing. All authors contributed to manuscript revision, read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work was supported by “Financiamiento Basal para Centros Científicos y Tecnológicos de Excelencia de ANID” Centro Ciencia & Vida [FB210008] (to Fundación Ciencia & Vida) from “Agencia Nacional de Investigación y Desarrollo de Chile (ANID)”. This work was also supported by the grant [MJFF-021112] from the Michael J. Fox Foundation for Parkinson’s research, and by [FONDECYT-1210013] (to RP) and [FONDECYT-11190251] (to CP) from ANID. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Macfarlane S, Macfarlane GT. Regulation of short-chain fatty acid production. Proc Nutr Soc. 2003;62:67–72. [DOI] [PubMed]

Marques FZ, Mackay CR, Kaye DM. Beyond gut feelings: how the gut microbiota regulates blood pressure. Nat Rev Cardiol. 2018;15:20–32. [DOI] [PubMed]

Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol. 2017;19:29–41. [DOI] [PubMed]

Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014;12:661–72. [DOI] [PubMed]

Soret R, Chevalier J, De Coppet P, Poupeau G, Derkinderen P, Segain JP, et al. Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats. Gastroenterology. 2010;138:1772–82. [DOI] [PubMed]

Mandl P, Kiss JP. Role of presynaptic nicotinic acetylcholine receptors in the regulation of gastrointestinal motility. Brain Res Bull. 2007;72:194–200. [DOI] [PubMed]

Campos-Acuña J, Elgueta D, Pacheco R. T-cell-driven inflammation as a mediator of the gut-brain axis involved in Parkinson’s disease. Front Immunol. 2019;10:239. [DOI] [PubMed] [PMC]

Sepahi A, Liu Q, Friesen L, Kim CH. Dietary fiber metabolites regulate innate lymphoid cell responses. Mucosal Immunol. 2021;14:317–30. [DOI] [PubMed] [PMC]

Prado C, Espinoza A, Martínez-Hernández JE, Petrosino J, Riquelme E, Martin AJM, et al. GPR43 stimulation on TCRαβ⁺ intraepithelial colonic lymphocytes inhibits the recruitment of encephalitogenic T-cells into the central nervous system and attenuates the development of autoimmunity. J Neuroinflammation. 2023;20:135. [DOI] [PubMed] [PMC]

10.

Liu J, Li H, Gong T, Chen W, Mao S, Kong Y, et al. Anti-neuroinflammatory effect of short-chain fatty acid acetate against Alzheimer’s disease via upregulating GPR41 and inhibiting ERK/JNK/NF-κB. J Agric Food Chem. 2020;68:7152–61. [DOI] [PubMed]

11.

Jaworska K, Kopacz W, Koper M, Szudzik M, Gawryś-Kopczyńska M, Konop M, et al. Enalapril diminishes the diabetes-induced changes in intestinal morphology, intestinal RAS and blood SCFA concentration in rats. Int J Mol Sci. 2022;23:6060. [DOI] [PubMed] [PMC]

12.

Lange O, Proczko-Stepaniak M, Mika A. Short-chain fatty acids—a product of the microbiome and its participation in two-way communication on the microbiome-host mammal line. Curr Obes Rep. 2023;12:108–26. [DOI] [PubMed] [PMC]

13.

Manjarres Z, Calvo M, Pacheco R. Regulation of pain perception by microbiota in Parkinson disease. Pharmacol Rev. 2024;76:7–36. [DOI] [PubMed]

14.

Saresella M, Marventano I, Barone M, La Rosa F, Piancone F, Mendozzi L, et al. Alterations in circulating fatty acid are associated with gut microbiota dysbiosis and inflammation in multiple sclerosis. Front Immunol. 2020;11:1390. [DOI] [PubMed] [PMC]

15.

Mizuno M, Noto D, Kaga N, Chiba A, Miyake S. The dual role of short fatty acid chains in the pathogenesis of autoimmune disease models. PLoS One. 2017;12:e0173032. [DOI] [PubMed] [PMC]

16.

Sun J, Xu J, Yang B, Chen K, Kong Y, Fang N, et al. Effect of Clostridium butyricum against microglia-mediated neuroinflammation in Alzheimer’s disease via regulating gut microbiota and metabolites butyrate. Mol Nutr Food Res. 2020;64:e1900636. [DOI] [PubMed]

17.

Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell. 2016;167:1469–80.e12. [DOI] [PubMed] [PMC]

18.

Chen SJ, Chen CC, Liao HY, Lin YT, Wu YW, Liou JM, et al. Association of fecal and plasma levels of short-chain fatty acids with gut microbiota and clinical severity in patients with Parkinson disease. Neurology. 2022;98:e848–58. [DOI] [PubMed] [PMC]

19.

Duscha A, Gisevius B, Hirschberg S, Yissachar N, Stangl GI, Dawin E, et al. Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism. Cell. 2020;180:1067–80.e16. [DOI] [PubMed]

20.

Nagpal R, Neth BJ, Wang S, Mishra SP, Craft S, Yadav H. Gut mycobiome and its interaction with diet, gut bacteria and alzheimer’s disease markers in subjects with mild cognitive impairment: a pilot study. EBioMedicine. 2020;59:102950. [DOI] [PubMed] [PMC]

21.

Liu S, Gao J, Zhu M, Liu K, Zhang HL. Gut microbiota and dysbiosis in Alzheimer’s disease: implications for pathogenesis and treatment. Mol Neurobiol. 2020;57:5026–43. [DOI] [PubMed] [PMC]

22.

Ho L, Ono K, Tsuji M, Mazzola P, Singh R, Pasinetti GM. Protective roles of intestinal microbiota derived short chain fatty acids in Alzheimer’s disease-type beta-amyloid neuropathological mechanisms. Expert Rev Neurother. 2018;18:83–90. [DOI] [PubMed] [PMC]

23.

Zhang L, Wang Y, Xiayu X, Shi C, Chen W, Song N, et al. Altered gut microbiota in a mouse model of Alzheimer’s disease. J Alzheimers Dis. 2017;60:1241–57. [DOI] [PubMed]

24.

Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Bürmann J, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat Disord. 2016;32:66–72. [DOI] [PubMed]

25.

Kump P, Wurm P, Gröchenig HP, Wenzl H, Petritsch W, Halwachs B, et al. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment Pharmacol Ther. 2018;47:67–77. [DOI] [PubMed] [PMC]

26.

Hu X, Jin H, Yuan S, Ye T, Chen Z, Kong Y, et al. Fecal microbiota transplantation inhibited neuroinflammation of traumatic brain injury in mice via regulating the gut-brain axis. Front Cell Infect Microbiol. 2023;13:1254610. [DOI] [PubMed] [PMC]

27.

Nagpal R, Neth BJ, Wang S, Craft S, Yadav H. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer’s disease markers in subjects with mild cognitive impairment. EBioMedicine. 2019;47:529–42. [DOI] [PubMed] [PMC]

28.

Zhang S, Lv S, Li Y, Wei D, Zhou X, Niu X, et al. Prebiotics modulate the microbiota-gut-brain axis and ameliorate cognitive impairment in APP/PS1 mice. Eur J Nutr. 2023;62:2991–3007. [DOI] [PubMed]

29.

Bonfili L, Cecarini V, Cuccioloni M, Angeletti M, Berardi S, Scarpona S, et al. SLAB51 probiotic formulation activates SIRT1 pathway promoting antioxidant and neuroprotective effects in an AD mouse model. Mol Neurobiol. 2018;55:7987–8000. [DOI] [PubMed] [PMC]

30.

Akbari E, Asemi Z, Daneshvar Kakhaki R, Bahmani F, Kouchaki E, Tamtaji OR, et al. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial. Front Aging Neurosci. 2016;8:256. [DOI] [PubMed] [PMC]